CG
OVID icon

Cutler Group’s Ovid Therapeutics OVID Stock Holding History

Cutler Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,100
Closed -$6K – 3216
2023
Q4 		$6K Hold
2,100
– – ﹤0.01% 2669
2023
Q3 		$8K Hold
2,100
– – ﹤0.01% 2611
2023
Q2 		$6K Hold
2,100
– – ﹤0.01% 2549
2023
Q1 		$5K Hold
2,100
– – ﹤0.01% 2745
2022
Q4 		$3K Hold
2,100
– – ﹤0.01% 3513
2022
Q3 		$3K Hold
2,100
– – ﹤0.01% 4007
2022
Q2 		$4K Hold
2,100
– – ﹤0.01% 3891
2022
Q1 		$6K Hold
2,100
– – ﹤0.01% 4032
2021
Q4 		$6K Hold
2,100
– – ﹤0.01% 4082
2021
Q3 		$7K Hold
2,100
– – ﹤0.01% 4230
2021
Q2 		$8K Hold
2,100
– – ﹤0.01% 4097
2021
Q1 		$8K Buy
2,100
+2,000
+2,000% +$6.64K ﹤0.01% 4007
2020
Q4 		$0 Buy
+100
New +$466 ﹤0.01% 5324

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cutler Group's OVID Position: Q1 2024 in Review

Cutler Group sold out of Ovid Therapeutics (OVID) in Q1 2024, closing a stake of 2,100 shares — an estimated $6K sold.

Cutler Group first reported a position in OVID in Q4 2020 and held it in 13 quarters. The position peaked at $8K in Q3 2023. 81 funds tracked by Wall St. Rank hold OVID as of Q1 2024.

  • Cutler Group reported no remaining Ovid Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 2,100 Ovid Therapeutics shares in Q1 2024, an estimated $6K.
  • Cutler Group first reported a position in Ovid Therapeutics in Q4 2020 and held it in 13 quarters.
  • Cutler Group's Ovid Therapeutics position peaked at $8K in Q3 2023.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.